Clinuvel granted orphan designation
Tuesday, 29 July, 2008
Clinuvel Pharmaceuticals' [ASX: CUV] lead compound afamelanotide (CUV1647) has been granted orphan-drug designation by the US FDA.
Afamelanotide is a photoreceptive drug designed for use in the management of erythopoietic porphyrias, a rare group of metabolic disorders which cause phototoxicity.
Orphan-drug designation allows for an accelerated review process by the FDA, seven-year exclusivity once approval is obtained, and various tax benefits and fee exemptions.
Afemelanotide is also being developed as a treatment for other UV-related skin disorders and for cancer prophylaxis.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
